INSB400

INSB400 is an early-development drug delivery product being developed by InSitu Biologics. It is designed for the local delivery of cancer drugs, providing a precise elution rate over a pre-programmed period of time. The goal of INSB400 is to deliver specific doses of anti-cancer therapeutics directly to targeted sites in the body, thereby maintaining therapeutic drug levels locally while minimizing systemic exposure and reducing severe adverse events commonly associated with systemic chemotherapy. The product utilizes a multi-phase, prolonged-release platform intended for loco-regional treatment and may offer both direct and trans-lymphatic routes for localized therapy. As of now, it remains in the investigational pre-clinical stage and has not yet entered clinical trials or been approved for sale[1][2][4][7].